ClinicalTrials.gg
RecruitingNCT07075016EVOLVE 1Updated Aug 19, 2025

Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

A Phase 3 interventional study of Venetoclax 400 and Placebo in Acute Myeloid Leukemia, sponsored by Stichting Hemato-Oncologie voor Volwassenen Nederland. Recruiting at 119 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-19.

Sponsored by Stichting Hemato-Oncologie voor Volwassenen Nederland · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
227
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 281 studies in Leukemia, Myeloid, Acute with a site in Germany — 32 open to participants now, 54 under way, 18 of them phase 3. Leukemia, Myeloid, Acute · Germany.

Planned enrollment
83rd of 261
227 · median 126
Started
2025
with 8 others
Phase 3
81 of 281
9 open now
Primary completion
2028-12
later than 35 of 53 live
Registered
275th of 281
by date

Among the 281 studies in Leukemia, Myeloid, Acute with a site in Germany, this one is the 83rd largest by planned enrollment of the 261 interventional ones that give a count, is one of 9 that started in 2025, is one of 81 in phase 3, reaches primary completion later than 35 of the 53 other live ones, and was the 275th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

32 of the 281 studies in Leukemia, Myeloid, Acute with a site in Germany are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 281 studies in Leukemia, Myeloid, Acute with a site in Germany, or all of them as a file.
02

Study summary

The standard treatment for patients with acute myeloid leukemia (AML) with an abnormality in the IDH1 gene, who are not eligible for intensive chemotherapy, is a combination of ivosidenib and azacitidine. In this study it is investigated whether adding venetoclax to the standard treatment can improve the outcome of the treatment of this specific form of AML. The safety is investigated and how well it works. In order to properly assess the value of venetoclax, the effect of venetoclax is compared with the effect of a placebo. A placebo is a product without an active ingredient, a 'fake medicinal product'.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • IDH1
  • Newly AML diagnosed
  • Ineligible for intensive chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient with newly diagnosed IDH1-mutated AML, or IDH1-mutated MDS/AML according to the 2022 International Consensus Classification (Appendix A). Patients with AML with both IDH1 and IDH2 mutation are eligible as well. Of note: in case both NPM1 and IDH1 are mutated and both EVOLVE-1 (HO173/AMLSG 3423/ACT-HOV-AML-001) and EVOLVE-2 (HO177/AMLSG 35-24/ACT-HOV-AML-002are open for inclusion at your site, then patients can only be included in the EVOLVE-1 trial (HO173)
  2. Central confirmation of IDH1 mutation in one of the dedicated central genetic laboratories.
  3. Age ≥ 18 years, no upper age limit.
  4. Patient is ineligible for intensive induction chemotherapy by meeting at least 1 of the following criteria:

    • older than or equal to 75 years of age ineligible for intensive chemotherapy per physician's discretion (with an performance status 0-2; Appendix C).
    • 18-74 years: patient is not eligible for standard chemotherapy because of any of the following co-morbidities: o ECOG performance status 2 or 3 (Appendix C). o Cardiac history of chronic heart failure requiring treatment; or with an ≤50%; or chronic stable angina.

      • DLCO ≤ 65% or ≤ 65%.
      • ≥ 30 mL/min to \<45 ml/min calculated by the Cockcroft Gault formula.
      • Moderate hepatic impairment with total > 1.5 to \< 3.0 x (ULN).
      • Any other comorbidity that the local physician assesses to be incompatible with intensive chemotherapy. If a patient meets this criterion, sponsor must be informed via HO173@erasmusmc.nl
  5. Patient must have a projected of at least 12 weeks (as assessed by the treating physician).
  6. Patient must have a white cell blood (WBC) count of \< 25 x 109/L. Hydroxyurea can be used prior to study enrollment to reduce the WBC count to meet this criterion.
  7. Adequate renal function as evidenced by serum creatinine ≤ 2.0 × upper limit of normal (ULN) or creatinine clearance >30 mL/min based on the Cockcroft-Gault (GFR).
  8. Adequate hepatic function as evidenced by:

    • Serum total bilirubin ≤ 3.0 × ULN unless considered due to Gilbert's disease, or leukemic involvement. If a patient meets this criterion, sponsor must be informed via HO173@erasmusmc.nl Page 30 of 117 HOVON 173 AML / AMLSG 34-23 / ACT-HOV-AML-001 Version 1.1, UK 11 FEB 2025
    • (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 3.0 × ULN, unless considered due to leukemic involvement. If a patient meets this criterion, sponsor must be informed via HO173@erasmusmc.nl
  9. Female patients :

    • of nonchildbearing potential must be: o (defined as at least 1 year without any menses). o documented surgically sterile (e.g. documented hysterectomy, bilateral oophorectomy or bilateral salpingectomy) or status posthysterectomy (at least 1 month prior to screening).
    • of (not surgically sterile and not postmenopausal) must agree to avoid pregnancy during the study and for 6 months after the final study drug administration o and have a negative urine or serum pregnancy test at screening.

      o and, if heterosexually active, agree to consistently apply one highly effective* method of in combination to a barrier method for the duration of the study and for 6 months after the final study drug administration.

    • must agree not to breastfeed starting at screening and throughout the study period, and for 1 month after the final study drug administration.
    • must agree not to donate ova starting at screening and throughout the study period, and for 6 months after the final study drug administration.
  10. Men must use a latex condom during any sexual contact with women of childbearing potential (WOCBP), even if they have undergone a successful vasectomy and must agree to avoid to father a child (while on therapy and for 6 months after the final study drug administration). In addition, their female partners of childbearing potential must use a highly effective method of birth control.
  11. Male patient must not donate sperm starting at screening and throughout the study period and for 6 months after the final study drug administration.
  12. Able to understand and willing to sign an form (ICF).
  13. Institutional Review Board/Independent Ethics Committee-approved written informed consent and privacy language as per national regulations must be obtained from the participant prior to any study-related procedures (including consent for withdrawal of prohibited medication, if applicable).

Exclusion criteria

Exclusion Criteria:

  1. Subject has previously been treated for AML; a treatment period with hydroxyurea to control WBC counts is allowed; prior treatment with a hypomethylating agent for MDS-EB is not allowed; prior treatment with erythropoiesis-stimulating agents or luspatercept for MDS is allowed.
  2. Acute promyelocytic leukemia (APL) with t(15;17)(q24.1;q21.2); PML-RARA; or one of the other pathognomonic variant chromosomal translocations / fusion genes.
  3. AML with BCR-ABL1; or myeloid blast crisis of CML
  4. Significant active cardiac disease within 3 months prior to the start of study treatment, including:

    - (NYHA) class III or IV congestive heart failure (Appendix F)

    - Myocardial infarction

    - Unstable angina

    • Severe cardiac arrhythmias
    • Congenital long syndrome of family member with this condition
    • QTcF >480 msec on screening electrogram (mean of triplicate recordings).
  5. Familial history of sudden death or polymorphic ventricular arrhythmia.
  6. Severe obstructive or restrictive ventilation disorder.
  7. History of stroke or intracranial hemorrhage within 6 months prior to randomization.
  8. Clinical symptoms suggestive of active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid (CSF) during screening is only required if there is a clinical suspicion of CNS involvement by leukemia during screening.
  9. Active infection, including or or (HIV) infection, that is uncontrolled prior to first dose of study treatment and may interfere with the study objectives or which could expose the patient to undue risk through the participation in the clinical trial; an infection controlled with an approved antibiotic/ antiviral/ antifungal treatment that is not a strong or moderate inducer is allowed. Patients with COVID-19 infection can be enrolled, if the patient has no symptoms and was tested negative twice by PCR test prior to inclusion in the trial.
  10. Immediate life-threatening, severe complications of leukemia such as uncontrolled bleeding and/or disseminated intravascular coagulation.
  11. Conditions that limit the ingestion or gastrointestinal absorption of orally administered drugs
  12. Patient with a currently active second . Patients are not considered to have a currently active malignancy, if they have completed therapy and are considered by their physician to be at \< 30% risk of relapse within one year. However, patients with the following history/concurrent conditions are allowed:

    • Basal or squamous cell carcinoma of the skin;
    • Carcinoma in situ of the cervix;
    • Carcinoma in situ of the breast;
    • Incidental histologic finding of prostate cancer.
  13. Receipt of live, attenuated vaccine within 30 days prior to the study inclusion (NOTE: patient, if enrolled, should not receive during the study and until 6 months after the therapy).
  14. Severe neurological or psychiatric disorder interfering with ability to give an .
  15. to any of the anti-leukemic agents used (as per SmPC). 16. Participation in other prospective studies with anti-leukemic and/or agents.

17. Patient taking Dabigatran unless they can be transferred to other medications within ≥5 half-lives prior to dosing. Patients taking other P-gP transporter-sensitive medications (see Appendix J) should be properly monitored during the study if they cannot be transferred to other medications." 18. Patients taking known strong cytochrome P450 (CYP) 3A4 inducers (see Appendix H), unless they can be transferred to other medications within ≥5 half-lives prior to dosing.

19. The patient is a pregnant or lactating woman, or plans to become pregnant during the study.

20. Patient who has once been screened and randomized into this HO173 trial but was considered ineligible cannot re-enter this trial at a later date.

-

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
227 participants (estimated)

Study arms

  • Placebo comparator
    Placebo comparator: Venetoclax-placebo

    day 1-28 Placebo Treatment will be on a continuous 28-day cycle schedule continued until disease relapse, disease progression, development of unacceptable toxicity, death, withdrawal of subject or other protocol defined criteria for discontinuation (which ever comes first)

    Drug: Placebo

  • Experimental
    Experimental: Venetoclax

    day 1-28 Venetoclax Treatment will be on a continuous 28-day cycle schedule continued until disease relapse, disease progression, development of unacceptable toxicity, death, withdrawal of subject or other protocol defined criteria for discontinuation (which ever comes first)

    Drug: Venetoclax 400

Interventions

  • DrugVenetoclax 400

    day 1-28 per cycle

  • DrugPlacebo

    day 1-28 per cycle

06

What researchers measure

Primary outcomes

  1. Event-free survival (EFS) in patients with newly diagnosed IDH1-mutated AML ineligible for intensive chemotherapy

    Event-free survival (EFS) in patients with newly diagnosed IDH1-mutated AML ineligible for intensive chemotherapy, measured from the date of randomization to the date of treatment failure, hematologic relapse from CR/CRh or death from any cause, whichever occurs first. Treatment failure is defined as lack of obtaining either CR or CRh by week 24. Patients evaluable for response but not achieving CR or CRh by week 24 will be considered a treatment failure at day 1 post randomization to avoid ambiguities of variable or prolonged periods without response. Patients who die before week 24 without response assessments will also be considered treatment failures at day 1 post randomization. Patients who are alive but not evaluable for response will be censored at day 1 post randomization. Patients who achieved CR or CRh by week 24 and are not known to have morphologic relapse or died will be censored at the date of the last clinical assessment.

    Time frame: 12 months after inclusion of last AML patient

Secondary outcomes

  1. Overall survival (OS) in patients with newly diagnosed IDH1-mutated AML

    Overall survival (OS) in patients with newly diagnosed IDH1-mutated AML, measured from the day of randomization to the date of death from any cause; patients not known to have died are censored on the date they were last known to be alive.

    Time frame: 12 months after inclusion of last AML patient

  2. Rate of CR/CRh in patients with newly diagnosed IDH1-mutated AML

    Rate of CR/CRh in patients with newly diagnosed IDH1-mutated AML, defined as the proportion of patients with CR/CRh at any time point during protocol therapy.

    Time frame: 12 months after inclusion of last AML patient

  3. Rate of CR in patients with newly diagnosed IDH1-mutated AML

    Rate of CR in patients with newly diagnosed IDH1-mutated AML, defined as the proportion of patients with CR at any time point during protocol therapy.

    Time frame: 12 months after inclusion of last AML patient

  4. Rate of CR/CRi in patients with newly diagnosed IDH1-mutated AML

    Rate of CR/CRi in patients with newly diagnosed IDH1-mutated AML, defined as the proportion of patients with CR/CRi at any time point during protocol therapy.

    Time frame: 12 months after inclusion of last AML patient

  5. Rates of CR, CR/CRh and CR/CRi without measurable residual disease as assessed by multicolor flow cytometry

    Rates of CR, CR/CRh and CR/CRi without measurable residual disease as assessed by multicolor flow cytometry (CRMRD-, CR/CRhMRD- and CR/CRiMRD-) in patients with newly diagnosed IDH1-mutated AML, defined as the proportion patients with CRMRD-, CR/CRhMRD- and CR/CRiMRD-, respectively, at any time point during protocol therapy.

    Time frame: 12 months after inclusion of last AML patient

  6. Time to achievement of response (CR, CR/CRh and CR/CRi) in patients with newly diagnosed IDH1-mutated AML

    Time to achievement of response (CR, CR/CRh and CR/CRi) in patients with newly diagnosed IDH1-mutated AML, defined as time from the date of randomization until the 1st occurrence of response.

    Time frame: 12 months after inclusion of last AML patient

  7. Duration of response (CR, CR/CRh and CR/CRi) in patients with newly diagnosed IDH1mutated AML

    Duration of response (CR, CR/CRh and CR/CRi) in patients with newly diagnosed IDH1mutated AML, measured from the date of achievement of a response until the date of hematologic relapse or death from any cause; patients without any of these events will be censored on the date of last clinical assessment.

    Time frame: 12 months after inclusion of last AML patient

  8. The rate of transfusion independence (platelets and RBC) in patients with newly diagnosed IDH1-mutated AML

    The rate of transfusion independence (platelets and RBC) in patients with newly diagnosed IDH1-mutated AML, defined as the proportion of patients who achieved transfusion independence; transfusion independence is defined as a period of at least 56 days with no transfusion between the first dose of study drug and the last dose of study drug + 30 days.

    Time frame: A period of at least 56 days with no transfusion between the first dose of study drug and the last dose of study drug + 30 days.

07

Study locations

2 of 119 sites recruiting

Showing the first 100 of 119 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2028, 40 months after the start.

Of 78 non-industry phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 66 and three quarters within 111. This study's planned 40 months is below that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2025
First posted
Jul 20, 2025
StartActual
Aug 5, 2025
Primary completionEst.
Dec 2028
CompletionEst.
Mar 2029
Last update
Aug 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07075016
Lead sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Collaborators
German-Austrian Acute Myeloid Leukemia Study Group, United Kingdom AML Research Network, Gruppo Italiano Malattie EMatologiche dell'Adulto, Swiss Group for Clinical Cancer Research (SAKK), Danish Acute Leukemia Group, Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias, Nordic AML Group
Responsible party
Sponsor
First posted
Jul 20, 2025
Start date
Aug 5, 2025
Primary completion
Dec 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Aug 19, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion